News | October 03, 2023
Briefs: Aurobindo Pharma and Balaxi Pharmaceuticals
Balaxi Healthcare Ecuador S.A.S. has become a Wholly Owned Subsidiary of the company
Balaxi Healthcare Ecuador S.A.S. has become a Wholly Owned Subsidiary of the company
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
The discoveries by the two Nobel Laureates were critical for developing effective mRNA vaccines against COVID-19
Dr. Karikó is the third Solvay Prize winner to become a Nobel Prize laureate
SigTuple’s AI100 with Shonit is the premier solution for AI assisted digital pathology
Diofan Ultra736 provides ultra-high water vapor barrier with excellent thermoformability, unlocking the potential to design thinner and more sustainable blister films
The introduction of 'Definisse Core Filler' is a testament to the company's premium scientific-based innovation
The U.S. FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
The aggregate foreign investment, including investment from other foreign investors may be up to 90.1% shareholding in the company
Post-acquisition of the balance 25% outstanding shares will result into Sun Pharma de México, S.A. de C.V. becoming a wholly-owned subsidiary of the company.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
